SpringWorks Therapeutics, Inc. was officially dropped from the S&P Biotechnology Select Industry Index, S&P Global BMI Index, and S&P TMI Index on July 1, 2025. This action follows the completion of its acquisition by Merck KGaA, Darmstadt, Germany.
The removal from these indices is a standard procedural consequence when a publicly traded company is acquired and subsequently delisted. SpringWorks is no longer an independent entity trading on the Nasdaq.
This change reflects the company's new corporate structure as part of Merck KGaA's healthcare business. The acquisition, valued at $3.4 billion, concluded on June 30, 2025, leading to the cessation of SpringWorks' independent stock trading.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.